Proxisense is pleased to announce the completion of its 2023 funding round, which raised approximately £1m of development capital from the Company’s existing investors, including Oxford Science Enterprises and the University of Oxford Innovation Fund (managed by Parkwalk Advisors).  This exceeds the Company’s 2023 goal and provides additional investment for Proxisense to continue the development of its advanced sensor technologies and its expansion into Pharmaceutical Process Analysis and Medical Diagnostics applications.  Large pharma partners are already working with Proxisense prototype sensors for Process Analysis, and a clinical trial in Medical Diagnostics for skin cancer is expected to commence in early 2024.

Paul Vickery, Chairman, said, “We are extremely pleased to complete this new fundraising with continued support from our investors, who have been with us from the beginning and helped us develop the company from its Oxford University roots.”

Nick Dixon-Clegg, a Partner at co-lead investor Oxford Science Enterprises, said: “The progress made by Proxisense with the development of its novel sensor technologies in Pharmaceutical Process Analytics and Medical Diagnostics, building on its Aerospace beginnings, is compelling. This investment will help drive the Company’s next stage of growth in these areas, and we look forward to seeing the full potential of these new applications being realised over the coming years.”